ASIAMEDIC LIMITED (505) Fair Value & Analysis
Healthcare · SG · Market cap 26.4M SGD
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 4 days ago
Share price −9.5% over the past month.
A solid business, screening 29% undervalued on our models.
What matters now
- The price is below even our cautious bear case (0.0223 SGD). The market is more pessimistic than our downside scenario.
- Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 0.0090 SGD – 0.0270 SGD · fair‑value band 0.0223 SGD – 0.0269 SGD · the 0.0190 SGD price screens below the 0.0246 SGD fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
ASIAMEDIC LIMITED (505) currently trades at 0.0190 SGD, while our model-based Fair Value estimate is 0.0246 SGD, implying the stock looks roughly 29.5% undervalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, ASIAMEDIC LIMITED generated revenue of 35.3M SGD at a net margin of 5.7%. Revenue grew 17.7% year over year. It earns a return on equity of 8.2%. Fundamentals as of Aug 13, 2026
Our scenario range runs from 0.0223 SGD (bear case) to 0.0269 SGD (bull case); at 0.0190 SGD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 41% below its 52-week high and 58% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -50% fair-value upside, at 29%, 505 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (0.0400 SGD) versus Asset-Based (0.0100 SGD). Highest evidence: Growth DCF (80).
Notify me when 505 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 45
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
AsiaMedic Limited provides healthcare services in Singapore. It offers diagnostic imaging and radiology services, such as magnetic resonance imaging, computed tomography, bone densitometry, ultrasound, mammography, and x-ray imaging services, as well as cardiovascular, musculoskeletal, ear, nose and throat, breast, body, and neuroradiology assessments to …
Full company description
AsiaMedic Limited provides healthcare services in Singapore. It offers diagnostic imaging and radiology services, such as magnetic resonance imaging, computed tomography, bone densitometry, ultrasound, mammography, and x-ray imaging services, as well as cardiovascular, musculoskeletal, ear, nose and throat, breast, body, and neuroradiology assessments to general practitioners, specialists, and hospitals; and positron emission tomography and computed tomography scans for cardiac and cancer imaging. The company also provides primary healthcare services; medical aesthetic services, including laser skin rejuvenation, non-surgical facelifts, dermal fillers, body contouring, and skincare solutions; medical arrangement, travel medical concierge, diagnostic scan, wellness, medical evacuation, and visa services; and pharmaceuticals and aesthetic products. In addition, it operates family clinics and a boutique aesthetic clinic. The company was incorporated in 1974 and is based in Singapore.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ASIAMEDIC LIMITED reported revenue of 35.2M SGD in FY2025 versus 18.3M SGD in FY2021, a compound +17.9%/yr. Reported net income was 2.0M SGD in FY2025, compounding +29.7%/yr from FY2021.
Watch 505: get an alert when its fair value changes →
Peer Group
Diagnostics & Research · 136 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $603.01 | $308.19 | -49% |
| Danaher Corporation DHR | $205.79 | $103.88 | -50% |
| WuXi AppTec Co 2359 | HK$198.90 | HK$157.39 | -21% |
| Lonza Group LONN | CHF 566.20 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $570.58 | $255.77 | -55% |
| Agilent Technologies, Inc A | $148.24 | $61.53 | -58% |
| Waters Corporation WAT | $416.15 | $121.96 | -71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | -44% |
| Illumina, Inc ILMN | $192.91 | $95.51 | -50% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | -57% |
Compare ASIAMEDIC LIMITED with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ASIAMEDIC LIMITED (505) overvalued or undervalued?
What is the fair value of 505?
What is the quality score of 505?
What is the revenue of ASIAMEDIC LIMITED (505)?
What is the net profit margin of 505?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track ASIAMEDIC LIMITED and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.